135 related articles for article (PubMed ID: 9649145)
1. VLA2 integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry.
Charpin C; Garcia S; Bergeret D; Andrac L; Horschowski N; Choux R; Lavaut MN
Br J Cancer; 1998 Jun; 77(12):2274-80. PubMed ID: 9649145
[TBL] [Abstract][Full Text] [Related]
2. ELAM selectin expression in breast carcinomas detected by automated and quantitative immunohistochemical assays.
Charpin C; Bergeret D; Garcia S; Andrac L; Martini F; Horschowski N; Choux R; Lavaut MN
Int J Oncol; 1998 May; 12(5):1041-8. PubMed ID: 9538126
[TBL] [Abstract][Full Text] [Related]
3. VCAM (IGSF) adhesion molecule expression in breast carcinomas detected by automated and quantitative immunocytochemical assays.
Charpin C; Garcia S; Andrac L; Horschowski N; Choux R; Lavaut MN
Hum Pathol; 1998 Sep; 29(9):896-903. PubMed ID: 9744304
[TBL] [Abstract][Full Text] [Related]
4. VLA(3)/integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry.
Garcia S; Bergeret D; Martini F; Andrac L; Horschowski N; Choux R; Levaut M; Charpin C
Int J Oncol; 1997 Oct; 11(4):849-56. PubMed ID: 21528284
[TBL] [Abstract][Full Text] [Related]
5. Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas.
Charpin C; Garcia S; Bouvier C; Devictor B; Andrac L; Lavaut MN; Allasia C
Br J Cancer; 1997; 76(3):340-6. PubMed ID: 9252201
[TBL] [Abstract][Full Text] [Related]
6. CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors.
Charpin C; Devictor B; Bergeret D; Andrac L; Boulat J; Horschowski N; Lavaut MN; Piana L
Am J Clin Pathol; 1995 Apr; 103(4):443-8. PubMed ID: 7726141
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
8. MMP-1 expression has an independent prognostic value in breast cancer.
Boström P; Söderström M; Vahlberg T; Söderström KO; Roberts PJ; Carpén O; Hirsimäki P
BMC Cancer; 2011 Aug; 11():348. PubMed ID: 21835023
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin quantitative immunocytochemical assays in breast carcinomas.
Charpin C; Garcia S; Bouvier C; Devictor B; Andrac L; Choux R; Lavaut M
J Pathol; 1997 Mar; 181(3):294-300. PubMed ID: 9155715
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
11. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
[TBL] [Abstract][Full Text] [Related]
12. Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer.
Tewari M; Pradhan S; Singh U; Singh TB; Shukla HS
Asian J Surg; 2010 Oct; 33(4):157-67. PubMed ID: 21377101
[TBL] [Abstract][Full Text] [Related]
13. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
14. p53 quantitative immunocytochemical analysis in breast carcinomas.
Charpin C; DeVictor B; Andrac L; Amabile J; Bergeret D; LaVaut MN; Allasia C; Piana L
Hum Pathol; 1995 Feb; 26(2):159-66. PubMed ID: 7860046
[TBL] [Abstract][Full Text] [Related]
15. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up.
Charpin C; Garcia S; Bonnier P; Martini F; Andrac L; Horschowski N; Lavaut MN; Allasia C
J Clin Oncol; 1998 Jun; 16(6):2025-31. PubMed ID: 9626199
[TBL] [Abstract][Full Text] [Related]
16. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein CD44 expression in colorectal neoplasms. An immuno-histochemical study including correlation with cathepsin D, extracellular matrix components, p53, Rb, bcl-2, c-erbB-2, EGFR and proliferation indices.
Ioachim E; Goussia A; Agnantis NJ
Virchows Arch; 1999 Jan; 434(1):45-50. PubMed ID: 10071234
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
[TBL] [Abstract][Full Text] [Related]
19. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators.
Charpin C; Vielh P; Duffaud F; Devictor B; Andrac L; Lavaut MN; Allasia C; Horschowski N; Piana L
J Natl Cancer Inst; 1994 Oct; 86(20):1539-45. PubMed ID: 7932810
[TBL] [Abstract][Full Text] [Related]
20. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
